The chemicals giant left markets unimpressed last week when it issued a profit warning
Headlines from the Proactive UK newsroom. ImmuPharma (LON:IMM) has signed an exclusive licence and development agreement with Avion Pharmaceuticals for its Lupus treatment Lupuzor. Avion will fund a new international Phase III trial up to a cost of US$25mln and commercialise the...
Get our market previews and stories before the main networks.
Not just the FTSE. Read about
opportunities from the whole
Hear directors at first-hand
or meet them in person at our events.
Watch IPOs and access on the same terms as the institutions.